Safety and PK Study of BIBF 1120 in Japanese Patients With IPF: Follow up Study From 1199.31(NCT01136174)

NCT01417156 · clinicaltrials.gov ↗

PHASE2

Phase

COMPLETED

Status

20

Enrollment

INDUSTRY

Sponsor class

Conditions

Pulmonary Fibrosis

Interventions

DRUG: Nintedanib
DRUG: Pirfenidoneone

Sponsor

Boehringer Ingelheim